HLB생명과학

067630KOSDAQ의료용품 및 기타 의약 관련제품 제조업

47.6 / 100

Reference Date: 2026-04-13

Financial Score12.0 / 40

News Sentiment15.6 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Rose 9.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Life Science operates four business divisions: Medicare, Biotech Development, Medical Device, and Energy, focusing on medical device manufacturing, pharmaceutical R&D, disposable syringe production, and solar EPC projects. Key clients include Abbott and Roche, and the company expanded its medical device market through the 2023 merger with Hwa Jin Medical and acquisition of Tinyco, which specializes in medical-grade nickel-titanium alloys.

Number of Employees

180people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.894.0Point

PBR

1.69Industry Average 1.622.5Point

Higher than industry avg (caution)

ROE

-28.70Industry Average -4.893.5Point

5.9x industry avg (excellent)

Debt Ratio

20.67Industry Average 8.880.0Point

2.3x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼25.5% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲5.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.8% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 0Negative 0Average Sentiment Score 75

Positive
HLB생명과학, 조직은행 허가 취득…인체조직 기반 제품 확대
HLB생명과학은 조직은행 허가를 취득하여 뼈, 연골, 근막, 피부 등 인체조직 이식재 사업을 확대할 계획입니다.
Positive
HLB생명과학, 인체조직 이식재 사업 확대한다...조직은행 허가 취득
HLB생명과학은 조직은행 허가 취득으로 인체조직 이식재 사업을 확대하며, 무세포 동종진피 주사제 '프리덤인젝트 리필' 공급을 본격화할 것으로 기대됩니다.

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 4,135Won52-week high 6,63052-week low 3,235

1-month return5.0Point

1m +9.25% (rising)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral정기주주총회결과2026-03-31
Neutral대표이사변경2026-03-31
Neutral기업설명회(IR)개최2026-03-26
Neutral기업설명회(IR)개최2026-03-26
Neutral사업보고서 (2025.12)2026-03-23